openPR Logo
Press release

Research report covers the Lung Cancer Therapeutics Market share and Growth, 2015-2025

01-05-2017 01:22 PM CET | Health & Medicine

Press release from: Future Market Insights

Research report covers the Lung Cancer Therapeutics Market

Lung cancer is a malignant tumor characterized by uncontrolled growth of cell tissues in the lung. Itis the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. American Lung Association has estimated that around 224,210new cases were diagnosed with lung cancer in the American region that accounts for approximately 13% of all the cancer cases diagnosed. Thus, with the rise in incidence rate of lung cancer, the demand for therapeutics is also expected to grow during the study period.

Based on the cancer cell types, lung cancer is broadly segmented as small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC segment accounts for approximately 80 to 90% of all lung cancers. Based on the cell shape and size, NSCLC is further divided to three subtypes, they are adenocarcinoma,large-cell carcinoma and squamous cell carcinoma. These NSCLC’s are primarily treated with the surgeries, at the same time chemotherapy is increasingly used for both pre-operative and post-operative treatment of the patients. The treatment options available for the NSCLC includesurgery, radiation therapy andchemotherapy. As per the American Cancer Society, it was estimated that in the United States approximately 195,000 peopleare suffering from NSCLC every year and the number of deaths from NSCLC areapproximately 135,000. The top five global brands that are commercially available in the market are Avastin, Tarceva, Alimta, Gemzar and Taxotere. Thus, all the above mentioned factors collectively drive the growth of the global lung cancer therapeutics market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-422

The global lung cancer therapeutics market can be segmented as follows:

By Drugs

Hycamtin

Taxotere

Gemzar

Alimta

Iressa

Avastin

Tarceva

Pipeline Drugs

Xalkori

Afatinib

Dacomitinib

ARQ 197

Talactoferrin

Increasing incidences of lung cancer due to rising smoking population is one of the major factors driving the growth of lung cancer therapeutics market. The risk of lung cancer is tenfold higher in smokers as compared to non-smokers. In addition, launch of premium priced drugs, new innovative radiation therapies coupled with rising incidences of NSCLC are the major driving factors for the growth of lung cancer therapeutics market. However, genericization of the major drugs might restrict the growth of this market.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-422

Geographically, North America and Europe dominates the global lung cancer therapeutics market. According to Lung Disease Research Funding, approximately 75,000 people in the U.S. die because of lung injury every year. The United States is the largest market for NSCLC owing to the high incidence rate, rise in aging population. In addition, with advent of new treatment therapies such as targeted drug therapy, stereotacticsare aiding patient population. Europe accounts to be the largest market after North America.While, Asia-Pacific countries such as India and China, South East Asia are the emerging regions for the global lung cancer therapeutics market due to high prevalence of this diseasecoupled with increasing healthcare awareness.

Players are adopting various strategies to expand their product portfolio and increase its geographical presence. New product development, agreements and collaborations and acquisitions are some of the important strategies adopted by the players in the global lung cancer therapeutics market. The prominent leading players of this market include AstrazenecaPlc, Eli Lilly and Company, GlaxoSmitKline, Hoffman-La Roche, BoehringerIngelheim GmbH, Pfizer Inc.,Sanofi-Aventis, among others.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Research report covers the Lung Cancer Therapeutics Market share and Growth, 2015-2025 here

News-ID: 406554 • Views:

More Releases from Future Market Insights

Workstation Software Market to Soar to USD 43.9 Billion by 2035, Fueled by 3D Modeling and VR Innovation
Workstation Software Market to Soar to USD 43.9 Billion by 2035, Fueled by 3D Mo …
Rising Demand for Workstation Software Across Industries The global workstation software market is set for robust growth, driven by increasing demand for advanced visualization, simulation, and design tools across industries such as manufacturing, architecture, media, and entertainment. Valued at USD 14.8 billion in 2025, the market is projected to reach USD 43.9 billion by 2035, registering a compound annual growth rate (CAGR) of 11.5%. This surge reflects the rising complexity of
Bean Flour Market Set for Robust Growth in the USA at 6.27% CAGR Through 2035
Bean Flour Market Set for Robust Growth in the USA at 6.27% CAGR Through 2035
The global bean flour market is entering a period of remarkable expansion, driven by surging demand for plant-based nutrition and gluten-free alternatives. Analysts forecast the market to grow from USD 5,075.3 million in 2025 to USD 9,262.0 million by 2035, reflecting a CAGR of 6.2%. This trajectory highlights an unparalleled opportunity for manufacturers to address evolving consumer preferences while enhancing sustainability and profitability. As the world shifts towards cleaner diets and
Blueberry Ingredient Market Set to Soar with 6.27% Growth in the USA by 2035
Blueberry Ingredient Market Set to Soar with 6.27% Growth in the USA by 2035
The blueberry ingredient industry has firmly established itself as a cornerstone of the functional foods, nutraceuticals, and natural flavoring sectors. Analysts project the market valuation to reach approximately USD 2.8 billion by 2025, with a robust CAGR of 6.5% forecasted from 2025 to 2035. This growth is being fueled by the escalating demand for clean-label products, plant-based formulations, and functional solutions across the food, beverage, and cosmetic industries. Click Here for
Activated Cake Emulsifier Market Set for 6.27% Growth in the USA, Poised to Transform Baking Innovation by 2035
Activated Cake Emulsifier Market Set for 6.27% Growth in the USA, Poised to Tran …
The activated cake emulsifier market is entering a transformative phase, driven by evolving consumer preferences toward premium, high-quality bakery products. Estimated to reach USD 1,343.2 million in 2025, the market is projected to achieve USD 2,360.5 million by 2035, representing a robust 5.8% CAGR over the next decade. This growth offers a strategic opportunity for manufacturers to meet rising consumer demands while future-proofing operations through innovation, regional customization, and sustainability. Click

All 5 Releases


More Releases for NSCLC

NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets. With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants. Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904 Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer. Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how